Ireland’s pharmaceutical pricing framework has been reset. The Framework Agreement on the Supply and Pricing of Medicines (FASPM) 2026–2029, signed on 3 March 2026 between the Irish government, the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland (MFI), governs medicine access and reimbursement for four years. Against persistent delays in new medicine approvals and pressure on HSE budgets, the agreement arrives at a pivotal moment for the sector in Ireland and Europe.

The FASPM represents the most ambitious structural reform of Irish medicines reimbursement in over a decade. It binds the State to credible review timelines while imposing tighter pricing discipline on industry. The agreement turns on three themes: accelerating patient access, a more rigorous pricing architecture, and new mechanisms to protect supply security.

The centrepiece is a formal commitment to a 180-day review process for new medicines, a target enshrined in the Health (Pricing and Supply of Medical Goods) Act 2013 but never achieved in practice. Schedule 4 sets staged milestones: 270 days by Q4 2027 and 180 days by Q1 2029. To deliver this, the HSE Drugs Group is to expand to between 33 and 37 members by end-2026, enabling consideration of up to 124 applications annually from 2027, more than double current capacity.

The pricing regime introduces hard ceilings across categories. Generics are capped at 40% of the October 2025 branded ex-factory price; biosimilars at 55%; patent-expired biologics reduce to 62.86% on loss of exclusivity, with a further 12.5% rebate payable to the HSE. Rebates on new medicines decline from 9% in 2026 to 5% by 2029, and annual price realignment, downward only, is benchmarked against 13 nominated European states.

The MFI agreement adds two provisions absent from the IPHA text. A value maintenance realignment of plus 1.5% per annum applies to a defined list of essential medicines, including oncology agents and antibiotics, recognising that unsustainably low prices are a structural driver of shortages. A tiered pricing mechanism permits generics in niche markets below approximately €2 million, where no Irish launch has occurred despite European availability, to enter at up to 70% of the reference originator price.

Three priorities will determine whether the framework delivers. Companies should front-load engagement with the National Centre for Pharmacoeconomics, issuing horizon-scan notifications 12 to 18 months before anticipated marketing authorisation to exploit expanded Drugs Group capacity. Biosimilar manufacturers should accelerate Irish market entry to trigger best-value biological medicine processes and unlock anticipated savings. Industry and the HSE should treat EU Joint Clinical Assessments under Regulation (EU) 2021/2282 as a shared resource, aligning dossier preparation with European evidence packages to compress domestic timelines.

The FASPM 2026–2029 positions Ireland to close the access gap with European peers while preserving pricing discipline that funds continued investment in new medicines. The 180-day target demands institutional change, not political commitment alone. If the HSE delivers its Drugs Group expansion and industry responds with earlier, higher-quality applications, Ireland has a credible path to becoming a reference market for equitable pharmaceutical access across the European Union.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)